Investigation of protein network of proteins in cardiovascular disease

References

• 1.
  Naghavi M, Wang H, Lozano R, Davis A, Liang X, Zhou M, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117-171.
• 2.
  Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. Circulation 1998; 97: 1876-1887.
• 3.
  Grundy SM, Bilheimer CD, Blackburn H, Brown WV, Kwiterovich Jr PO, et al. Rationale of the diet-heart statement of the American heart association report of nutrition committee. Circulation 1982; 17: 16-20.
• 4.
  Kratz M. Dietary cholesterol, atherosclerosis and coronary heart disease. Atherosclerosis: Diet and Drugs: Springer; 2005; p. 195-213.
• 5.
  Kasper D, Braunwald E, Fauci A, Hauser S, Longo D. Approach to the patient with cardiovascular disease: disorders of the cardiovascular system: Harrison's principles of internal medicine. New York: McGraw-Hill; 2008; p. 442-450.
• 6.
  Amani F, Hajizadeh E, Hoseinian F. Survival rate in MI patients. Koomesh 2008; 9: 131-138.
• 7.
  Lubell DL. Drawbacks and limitations of computed tomography. Tex Heart Inst J 2005; 32: 250-255.
• 8.
  Price AN, Cheung KK, Cleary JO, Campbell AE, Riegler J, Lythgoe MF. Cardiovascular magnetic resonance imaging in experimental models. Open Cardiovasc Med J 2010; 4: 278-292.
• 9.
  Karakas M, Koenig W. CRP in cardiovascular disease. Herz 2009; 34: 607-613.
• 10.
  Ridker PM. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. Clinic Chem 2009; 55: 209-215.
• 11.
  Lowe GD, Yarnell JW, Rumley A, Bainton D, Sweetnam PM. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the speedwell study are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001; 21: 603-610.
• 12.
  McGregor E, Dunn MJ. Proteomics of heart disease. Hum Mol Genet 2003; 12: 135-144.
• 13.
  Sharma P, Cosme J, Gramolini AO. Recent proteomic advances in cardiac cells. J Proteomics 2013; 81: 3-10.
• 14.
  Askevold ET, Gullestad L, Nymo S, Kjekshus J, Yndestad A, Latini R, et al. Ecreted frizzled related protein 3 in chronic heart failure: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA). PLoS One 2015; 10: e0133970.
• 15.
  Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: update 2010. Am Heart J 2010; 160: 583-594.
• 16.
  Deng N, Zhang J, Zong C, Wang Y, Lu H, Yang P, et al. Phosphoproteome analysis reveals regulatory sites in major pathways of cardiac mitochondria. Mol Cell Proteomics 2011; 10: 110-117.
• 17.
  Safari-Alighiarloo N, Taghizadeh M, Rezaei-Tavirani M, Goliaei B, Peyvandi AA. Protein-protein interaction networks (PPI) and complex diseases. Gastroenterol Hepatol Bed Bench 2014; 7: 17-31.
• 18.
  Safaei A, Tavirani MR, Oskouei AA, Azodi MZ, Mohebbi SR, Nikzamir AR. Protein-protein interaction network analysis of cirrhosis liver disease. Gastroenterol Hepatol Bed Bench 2016; 9: 114-123.
• 19.
  Zamanian-Azodi M, Rezaei-Tavirani M, Rahmati-Rad S, Hasanzadeh H, Tavirani MR, Seyyedi SS. Protein-Protein Interaction Network could reveal the relationship between the breast and colon cancer. Gastroenterol Hepatol Bed Bench 2015; 8: 215-224.
• 20.
  Rezaei-Tavirani M, Zamanian-Azodi M, Rajabi S, Masoudi-Nejad A, Rostami-Nejad M, Rahmatirad S. Protein clustering and interactome analysis in parkinson and Alzheimer's diseases. Arch Iran Med 2016; 19: 101-109.
• 21.
  Abad S, Alijani S, Kia H, Zali H, Karim S, Pashaie M. Bioinformatics analysis of E. coli causing mastitis in Holstein dairy cattle by using microarray data. Koomesh 2015; 17: 214-223.
• 22.
  Re M, Mesiti M, Valentini G. A fast ranking algorithm for predicting gene functions in biomolecular networks. IEEE/ACM Trans Comput Biol Bioinform 2012; 9: 1812-1818.
• 23.
  Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q. GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol 2008; 9: S4.
• 24.
  Zali H, Tavirani MR. Meningioma protein-protein interaction network. Arch Iran Med 2014; 17: 262-272.
• 25.
  Yu H, Kim PM, Sprecher E, Trifonov V, Gerstein M. The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol 2007; 3: e59.
• 26.
  Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504.
• 27.
  Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, et al. STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res 2013; 41: 808-815.
• 28.
  Rivera CG, Vakil R, Bader JS. NeMo: network module identification in Cytoscape. BMC Bioinformatics 2010; 11: S61.
• 29.
  Liu H, Hu ZZ, Wu CH. DynGO: a tool for visualizing and mining of Gene Ontology and its associations. BMC Bioinformatics 2005; 6: 201-209.
• 30.
  Jeong H, Mason SP, Barabsi A-L, Oltvai ZN. Lethality and centrality in protein networks. Nature 2001; 411: 41-42.
• 31.
  Barabasi AL, Oltvai ZN. Network biology: understanding the cell's functional organization. Nat Rev Genet 2004; 5: 101-113.
• 32.
  Consortium I-RMRA. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 2012; 379: 1214-1224.
• 33.
  Barallobre-Barreiro J, Didangelos A, Schoendube FA, Drozdov I, Yin X, Fernndez-Caggiano M, et al. Proteomics analysis of cardiac extracellular matrix remodeling in a porcine model of ischemia/reperfusion injury. Circulation 2012; 125: 789-802.
• 34.
  Chaanine AH, Hajjar RJ. AKT signalling in the failing heart. Eur J Heart Fail 2011; 13: 825-829.
• 35.
  Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 2003; 4: 1-9.
• 36.
  Chien KR. Molecular basis of cardiovascular disease: Saunders; 2004; p. 30-35.
• 37.
  Guffanti A. Modeling molecular networks: a systems biology approach to gene function. Genome Biol 2002; 3: 4031.1-3.
• 38.
  Bakail M, Ochsenbein F. Targeting proteinprotein interactions, a wide open field for drug design. Curr Pharm Biotechnol 2016; 19: 19-27.
• 39.
  Weber KT. Extracellular matrix remodeling in heart failure a role for de novo angiotensin II generation. Circulation 1997; 96: 4065-4082.
• 40.
  Rodriguez-Feo J, Sluijter J, de Kleijn D, Pasterkamp G. Modulation of collagen turnover in cardiovascular disease. Curr Pharm Des 2005; 11: 2501-2514.
• 41.
  Luneva O, Brazhe N, Maksimova N, Rodnenkov O, Parshina EY, Bryzgalova NY, et al. Ion transport, membrane fluidity and haemoglobin conformation in erythrocyte from patients with cardiovascular diseases: role of augmented plasma cholesterol. Pathophysiol 2007; 14: 41-46.
• 42.
  Ferguson-Smith AC, Chen Y-F, Newman MS, May LT, Sehgal PB, Ruddle FH. Regional localization of the interferon-2B-cell stimulatory factor 2/hepatocyte stimulating factor gene to human chromosome 7p15-p21. Genomics 1988; 2: 203-208.
• 43.
  van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 1997; 176: 439-444.
• 44.
  Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease The PRIME study. Arterioscler Thromb Vasc Biol 2003; 23: 1255-1261.
• 45.
  Shlipak MG, Ix JH, Bibbins-Domingo K, Lin F, Whooley MA. Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study. Am J Med 2008; 121: 50-57.
• 46.
  Lee JK, Bettencourt R, Brenner D, Le TA, Barrett-Connor E, Loomba R. Association between serum interleukin-6 concentrations and mortality in older adults: the Rancho Bernardo study. PLoS One 2012; 7: e34218.
• 47.
  Van der Poll T, Levi M, Hack CE, Ten Cate H, Van Deventer S, Eerenberg A, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 1253-1259.
• 48.
  Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993; 77: 1690-1694.
• 49.
  Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, et al. Primary prevention of coronary heart disease: guidance from framingham a statement for healthcare professionals from the AHA task force on risk reduction. Circulation 1998; 97: 1876-1887.
• 50.
  Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-1585.
• 51.
  Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, Di Franco M, et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 2003; 51: 295-300.
• 52.
  Hou Zh, Lu B, Gao Y, Cao Hl, Yu Ff, Jing N, et al. Matrix metalloproteinase-9 (MMP-9) and myeloperoxidase (MPO) levels in patients with nonobstructive coronary artery disease detected by coronary computed tomographic angiography. Acad Radio 2013; 20: 25-31.
• 53.
  Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 2005; 85: 1-31.
• 54.
  Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-2579.
• 55.
  Mohammed F, Smookler D, Khokha R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis 2003; 62: 43-47.
• 56.
  Abeyrathna P, Su Y. The critical role of Akt in cardiovascular function. Vascul Pharmacol 2015; 74: 38-48.
• 57.
  Shiraishi I, Melendez J, Ahn Y, Skavdahl M, Murphy E, Welch S, et al. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ Res 2004; 94: 884-891.
• 58.
  Lpez B, Gonzlez A, Dez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010; 12: 1645-1654.